AR024558A1 - COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME - Google Patents
COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAMEInfo
- Publication number
- AR024558A1 AR024558A1 ARP000102690A ARP000102690A AR024558A1 AR 024558 A1 AR024558 A1 AR 024558A1 AR P000102690 A ARP000102690 A AR P000102690A AR P000102690 A ARP000102690 A AR P000102690A AR 024558 A1 AR024558 A1 AR 024558A1
- Authority
- AR
- Argentina
- Prior art keywords
- processes
- compositions
- produce
- same
- beta peptide
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
- 238000011146 sterile filtration Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se refiere a procesos para preparar composiciones que comprenden al péptido A beta solubilizado o a suspensiones del péptido A beta ajustando el pH losuficiente como para lograr la solubilizacion, y la filtracion estéril de las mismas, a métodos paratratar de prevenir la enfermedad de Alzheimer con lascomposiciones obtenidas y a procesos para producir las mismas.It refers to processes for preparing compositions comprising the solubilized beta A peptide or suspensions of the beta A peptide by adjusting the pH sufficient to achieve solubilization, and sterile filtration thereof, to methods to try to prevent Alzheimer's disease with the compositions obtained and processes to produce them.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13704799P | 1999-06-01 | 1999-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024558A1 true AR024558A1 (en) | 2002-10-16 |
Family
ID=22475602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102690A AR024558A1 (en) | 1999-06-01 | 2000-05-31 | COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1181040A1 (en) |
| JP (1) | JP2003519620A (en) |
| KR (1) | KR20020016813A (en) |
| CN (1) | CN1353615A (en) |
| AR (1) | AR024558A1 (en) |
| AU (1) | AU5726100A (en) |
| BG (1) | BG106249A (en) |
| BR (1) | BR0011251A (en) |
| CA (1) | CA2374897A1 (en) |
| CZ (1) | CZ20014150A3 (en) |
| EE (1) | EE200100649A (en) |
| HK (1) | HK1045938A1 (en) |
| HR (1) | HRP20010901A2 (en) |
| IL (1) | IL146575A0 (en) |
| IS (1) | IS6182A (en) |
| MX (1) | MXPA01012355A (en) |
| NO (1) | NO20015859L (en) |
| NZ (1) | NZ515744A (en) |
| PE (1) | PE20010212A1 (en) |
| PL (1) | PL352575A1 (en) |
| RU (1) | RU2001135800A (en) |
| SK (1) | SK17012001A3 (en) |
| TR (1) | TR200103476T2 (en) |
| WO (1) | WO2000072870A1 (en) |
| ZA (1) | ZA200109704B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| WO2002025279A2 (en) * | 2000-09-19 | 2002-03-28 | Evotec Neurosciences Gmbh | Use of amyloid precursor protein for treating brain amyloidosis |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (en) | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
| PE20050627A1 (en) | 2003-05-30 | 2005-08-10 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE |
| SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| WO2006066049A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
| EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| JP5033868B2 (en) | 2006-03-23 | 2012-09-26 | バイオアークティック ニューロサイエンス アーベー | Improved protofibril selective antibody and use thereof |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| PL2182983T3 (en) | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Treatment of amyloidogenic diseases with humanised anti-abeta antibodies |
| JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| PE20170768A1 (en) | 2014-07-10 | 2017-07-04 | Eisai Randd Man Co Ltd | IMPROVED AB PROTOFIBRILL BINDING ANTIBODIES |
| IL318754A (en) | 2016-01-08 | 2025-04-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| MX2018008050A (en) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability. |
| US11413351B2 (en) | 2016-01-08 | 2022-08-16 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with carrier attachment at the ring moiety |
| CN113423384B (en) | 2019-02-11 | 2024-01-05 | 阿森迪斯药物生长障碍股份有限公司 | Dry pharmaceutical formulations of CNP conjugates |
| CN114957438B (en) * | 2022-06-28 | 2024-04-02 | 福建亿彤生物科技有限公司 | Human Aβ1-42 antigenic determinant polypeptide for detecting Alzheimer's disease and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE153534T1 (en) * | 1990-04-27 | 1997-06-15 | John Mcmichael | METHOD AND COMPOSITION FOR TREATING CNS DISEASES CAUSED BY ABNORMAL BETA-AMYLOID PROTEIN |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2000
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/en not_active Application Discontinuation
- 2000-05-31 AR ARP000102690A patent/AR024558A1/en unknown
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Application Discontinuation
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/en not_active Withdrawn
- 2000-06-01 CN CN00808374A patent/CN1353615A/en active Pending
- 2000-06-01 HK HK02106241.2A patent/HK1045938A1/en unknown
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/en unknown
- 2000-06-01 IL IL14657500A patent/IL146575A0/en unknown
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/en unknown
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/en not_active Withdrawn
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/en unknown
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/en unknown
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/en not_active Application Discontinuation
- 2000-06-01 PL PL00352575A patent/PL352575A1/en not_active Application Discontinuation
- 2000-06-01 HR HR20010901A patent/HRP20010901A2/en not_active Application Discontinuation
- 2000-06-01 EE EEP200100649A patent/EE200100649A/en unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/en unknown
-
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/en unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/en not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200103476T2 (en) | 2002-04-22 |
| NO20015859D0 (en) | 2001-11-30 |
| BR0011251A (en) | 2002-03-05 |
| PE20010212A1 (en) | 2001-02-22 |
| NO20015859L (en) | 2002-02-01 |
| KR20020016813A (en) | 2002-03-06 |
| CZ20014150A3 (en) | 2002-05-15 |
| NZ515744A (en) | 2004-04-30 |
| MXPA01012355A (en) | 2003-06-24 |
| WO2000072870A1 (en) | 2000-12-07 |
| SK17012001A3 (en) | 2002-06-04 |
| CA2374897A1 (en) | 2000-12-07 |
| PL352575A1 (en) | 2003-08-25 |
| EP1181040A1 (en) | 2002-02-27 |
| RU2001135800A (en) | 2003-08-20 |
| BG106249A (en) | 2002-08-30 |
| HK1045938A1 (en) | 2002-12-20 |
| CN1353615A (en) | 2002-06-12 |
| IL146575A0 (en) | 2002-07-25 |
| IS6182A (en) | 2001-11-29 |
| EE200100649A (en) | 2003-02-17 |
| ZA200109704B (en) | 2003-02-26 |
| JP2003519620A (en) | 2003-06-24 |
| HRP20010901A2 (en) | 2003-04-30 |
| AU5726100A (en) | 2000-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024558A1 (en) | COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THE SAME | |
| DOP2002000429A (en) | IMIDAZOTRIAZINAS | |
| EA200200249A1 (en) | DERIVATIVES 3 (5) -UREIDOPYRAZOL, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS ANTI-TUMOR AGENTS | |
| BRPI0409611A (en) | piperazine derivatives and their use for the treatment of neurological and psychiatric disorders | |
| ECSP055719A (en) | TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| BR0017026A (en) | Lipeptides as antibacterial agents | |
| DE60037139D1 (en) | POLY-HYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND ALPHA-SYNUCLEIN FIBRIL DISEASES | |
| ES2191511A1 (en) | Erythropoietin derivatives | |
| DE60019122D1 (en) | CHANGED FACTOR VIII | |
| GT199900067A (en) | NEW 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURTIC DEDERMATOSIS. | |
| DE60318839D1 (en) | 2,6-CHINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USES FOR THE TREATMENT OF VLA-4 RELATED DISEASES | |
| ATE311226T1 (en) | THE GLYCINE BETAIN FOR ITS ANTITHROMBOTIC USE | |
| TW200716152A (en) | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture | |
| MX9305248A (en) | DIARILPIPERAZINOACETAMIDA COMPOUNDS. | |
| ATE281432T1 (en) | C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOGUE | |
| CY1110644T1 (en) | 5,6,7-Trihydroxyheptanoic acid and its analogues for the treatment of ophthalmic diseases related to hypercapillary and angiogenic diseases | |
| WO2003047507A3 (en) | Factor viii c2 domain variants | |
| ATE234636T1 (en) | CONJUGATE COMPRISING AN ACTIVE INGREDIENT, A POLYPEPTIDE AND A POLYETHER | |
| ATE283256T1 (en) | C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOGUE | |
| EA200100700A1 (en) | GENES AND PROTEINS AND THEIR APPLICATION | |
| UY27451A1 (en) | 2,5-DIAMIDOINDOLES REPLACED AND ITS USE | |
| ES2185837T3 (en) | USE OF THEOPHYLIN DERIVATIVES FOR THE TREATMENT AND PROFILAXIS OF SHOCK DISEASES, NEW XANTINE COMPOUNDS AND PROCEDURES FOR PRODUCTION. | |
| BR9807312A (en) | (4-Piperidinyl) -1h-2-benzopyran derivatives useful as antipsychotic agents | |
| BRPI0408077A (en) | compositions and methods for prevention and treatment of endotoxin-related diseases and conditions | |
| ECSP003504A (en) | COMPOSITIONS OF PEPTIDE A - BETA AND PROCESSES TO PRODUCE THE SAME |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure |